Author response to letter from Song et al

Affiliations

Comment

Ken Song et al. J Matern Fetal Neonatal Med. 2014 Jun.

. 2014 Jun;27(9):972.

doi: 10.3109/14767058.2013.841384. Epub 2013 Oct 8.

No abstract available

Comment on

Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population.
Song K, Musci TJ, Caughey AB. Song K, et al. J Matern Fetal Neonatal Med. 2013 Aug;26(12):1180-5. doi: 10.3109/14767058.2013.770464. Epub 2013 Mar 6. J Matern Fetal Neonatal Med. 2013. PMID: 23356557 Free PMC article.

Clinical utility and cost of non-invasive prenatal testing.
Cuckle H, Benn P, Pergament E. Cuckle H, et al. J Matern Fetal Neonatal Med. 2014 Feb;27(3):320-1. doi: 10.3109/14767058.2013.807239. Epub 2013 Jul 30. J Matern Fetal Neonatal Med. 2014. PMID: 23875873 No abstract available.
Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population.
Song K, Musci TJ, Caughey AB. Song K, et al. J Matern Fetal Neonatal Med. 2013 Aug;26(12):1180-5. doi: 10.3109/14767058.2013.770464. Epub 2013 Mar 6. J Matern Fetal Neonatal Med. 2013. PMID: 23356557 Free PMC article.
Pre-natal screening for Down's syndrome.
Phillips A, Wakeman A. Phillips A, et al. J Public Health Med. 1994 Mar;16(1):114-5; author reply 116-7. doi: 10.1093/oxfordjournals.pubmed.a042915. J Public Health Med. 1994. PMID: 8080557 No abstract available.
Cost-effectiveness of Down syndrome screening paradigms.
Caughey AB, Kaimal AJ, Odibo AO. Caughey AB, et al. Clin Lab Med. 2010 Sep;30(3):629-42. doi: 10.1016/j.cll.2010.04.007. Clin Lab Med. 2010. PMID: 20638577 Review.
[Serum analysis in pregnant women. Mass screening is an effective way to discover chromosome aberrations--arguments for and against].
Kristoffersson U, Nørgaard-Pedersen B. Kristoffersson U, et al. Lakartidningen. 1995 Mar 22;92(12):1205-6, 1211-2. Lakartidningen. 1995. PMID: 7535873 Review. Swedish. No abstract available.